Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited, stands as a cornerstone in the Indian pharmaceutical sector, offering extensive healthcare solutions globally. Established in 1952 by the pioneering entrepreneur Mr. Ramanbhai B. Patel, the company has undergone substantial growth, achieving a remarkable turnover exceeding Rs. 17,000 crores in FY-21, a significant leap from its humble beginnings with a turnover of Rs. 250 crores in 1995. Renowned for its comprehensive approach to healthcare, Zydus boasts a robust portfolio encompassing formulations, active pharmaceutical ingredients, animal healthcare, and wellness products. This enduring commitment to excellence is underscored by its dedication to addressing unmet healthcare needs and fostering healthier communities worldwide, thereby solidifying its position as a leader in the pharmaceutical industry.
Zydus Lifesciences Q4 FY24 Results Highlights
- Net Profit: Zydus Lifesciences reported a net profit of Rs 1,182 crore for Q4, marking a four-fold increase from Rs 296 crore in the same period last year.
- Revenue: The company’s revenue reached Rs 5,533 crore, reflecting a 10 percent increase from the previous year.
- EBITDA: Earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose to Rs 1,629.8 crore from Rs 1,257 crore.
- EBITDA Margin: The EBITDA margin improved to 29.5 percent, up from 25 percent a year ago.
- Dividend: The board declared a final dividend of Rs 3 per equity share.
- Chronic Therapies: Chronic therapies accounted for 41.2 percent of the total India business, representing an increase of 360 basis points over the last three years.
- India Branded Business: The India branded business experienced an 8 percent year-over-year growth.
- FMCG Sector: The FMCG sector witnessed a gradual recovery, particularly with increased demand in rural India.
- Product Launches and Approvals (US): Zydus Lifesciences launched five new products and received approvals for 12 new products (including four tentative approvals) in the US during the quarter.
- Full Year Product Activity: The company filed 20 ANDAs, received approvals for 46 new products (including five tentative approvals), and launched 29 new products throughout the year.
- UK Expansion: Zydus Lifesciences is focusing on scaling up operations in the UK, emphasizing differentiated and niche generics, as well as specialty products.
- US FDA Inspection: The company received an inspection report from the US FDA for the injectable manufacturing site in Jarod, Gujarat, with 10 observations.
- Company Background: Founded as Cadila Laboratories in 1952, Zydus Lifesciences has evolved into one of the top five pharmaceutical companies in India and a leading player in the US generic market.
How to purchase Zydus Lifescience shares?
Below are the trading platforms that you can use to purchase Zydus Lifescience Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
Zydus Lifesciences Share Price Target: 2024, 2025 to 2030
Zydus Lifesciences Share Price Target 2024
| When | Maximum Price | Minimum Price |
| May 2024 | 1,115.00 | 969.57 |
| June 2024 | 1,155.14 | 1,004.47 |
| July 2024 | 1,143.59 | 994.43 |
| August 2024 | 1,189.34 | 1,034.21 |
| September 2024 | 1,236.91 | 1,075.57 |
| October 2024 | 1,212.66 | 1,054.48 |
| November 2024 | 1,261.16 | 1,096.66 |
| December 2024 | 1,273.77 | 1,107.63 |
In May 2024, Zydus Lifesciences is expected to reach a maximum price of 1,115.00 and a minimum price of 969.57. As we progress through the year, June may see the maximum price rise to 1,155.14, with the minimum price at 1,004.47. By December, Zydus Lifesciences is projected to experience a maximum price of 1,273.77 and a minimum price of 1,107.63.
Zydus Lifesciences Share Price Prediction 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 1,286.51 | 989.62 |
| February 2025 | 1,299.51 | 999.62 |
| March 2025 | 1,326.80 | 1,020.61 |
| April 2025 | 1,313.66 | 1,010.51 |
| May 2025 | 1,275.40 | 981.08 |
| June 2025 | 1,332.79 | 1,025.22 |
| July 2025 | 1,306.66 | 1,005.12 |
| August 2025 | 1,347.07 | 1,036.21 |
| September 2025 | 1,363.24 | 1,048.64 |
| October 2025 | 1,398.68 | 1,075.91 |
| November 2025 | 1,433.65 | 1,102.80 |
| December 2025 | 1,498.16 | 1,152.43 |
As we step into January 2025, Zydus Lifesciences is projected to reach a maximum price of 1,286.51 and a minimum price of 989.62. Moving through the year, February may see the maximum price rise to 1,299.51, with the minimum price at 999.62. By December, Zydus Lifesciences is expected to experience a maximum price of 1,498.16 and a minimum price of 1,152.43.
Zydus Lifesciences Share Price Target 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 1,543.11 | 1,187.00 |
| February 2026 | 1,504.53 | 1,157.33 |
| March 2026 | 1,534.62 | 1,180.48 |
| April 2026 | 1,565.94 | 1,204.57 |
| May 2026 | 1,550.43 | 1,192.64 |
| June 2026 | 1,589.19 | 1,222.46 |
| July 2026 | 1,558.03 | 1,198.49 |
| August 2026 | 1,606.22 | 1,235.55 |
| September 2026 | 1,638.34 | 1,260.26 |
| October 2026 | 1,680.94 | 1,293.03 |
| November 2026 | 1,722.96 | 1,325.36 |
| December 2026 | 1,766.04 | 1,358.49 |
Zydus Lifesciences Share Price Target 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 1,783.70 | 1,372.08 |
| February 2027 | 1,829.43 | 1,407.26 |
| March 2027 | 1,900.78 | 1,462.14 |
| April 2027 | 1,863.51 | 1,433.47 |
| May 2027 | 1,809.24 | 1,391.72 |
| June 2027 | 1,890.65 | 1,454.35 |
| July 2027 | 1,853.58 | 1,425.83 |
| August 2027 | 1,910.91 | 1,469.93 |
| September 2027 | 1,977.79 | 1,521.38 |
| October 2027 | 2,029.21 | 1,560.93 |
| November 2027 | 2,079.94 | 1,599.95 |
| December 2027 | 2,131.94 | 1,639.95 |
Zydus Lifesciences Share Price Target 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 2,174.58 | 1,672.75 |
| February 2028 | 2,230.34 | 1,715.64 |
| March 2028 | 2,317.32 | 1,782.55 |
| April 2028 | 2,271.88 | 1,747.60 |
| May 2028 | 2,205.71 | 1,696.70 |
| June 2028 | 2,304.97 | 1,773.05 |
| July 2028 | 2,259.77 | 1,738.29 |
| August 2028 | 2,329.66 | 1,792.05 |
| September 2028 | 2,411.20 | 1,854.77 |
| October 2028 | 2,473.89 | 1,902.99 |
| November 2028 | 2,535.74 | 1,950.57 |
| December 2028 | 2,599.13 | 1,999.33 |
Zydus Lifesciences Share Price Target 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 2,651.11 | 2,039.32 |
| February 2029 | 2,719.09 | 2,091.61 |
| March 2029 | 2,825.14 | 2,173.18 |
| April 2029 | 2,769.74 | 2,130.57 |
| May 2029 | 2,689.07 | 2,068.52 |
| June 2029 | 2,810.08 | 2,161.60 |
| July 2029 | 2,754.98 | 2,119.21 |
| August 2029 | 2,840.18 | 2,184.76 |
| September 2029 | 2,939.59 | 2,261.22 |
| October 2029 | 3,016.02 | 2,320.02 |
| November 2029 | 3,091.42 | 2,378.02 |
| December 2029 | 3,168.71 | 2,437.47 |
Zydus Lifesciences Share Price Prediction 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 3,232.08 | 2,486.22 |
| February 2030 | 3,314.95 | 2,549.96 |
| March 2030 | 3,444.24 | 2,649.41 |
| April 2030 | 3,376.70 | 2,597.46 |
| May 2030 | 3,278.35 | 2,521.81 |
| June 2030 | 3,425.88 | 2,635.29 |
| July 2030 | 3,358.70 | 2,583.62 |
| August 2030 | 3,462.58 | 2,663.52 |
| September 2030 | 3,583.77 | 2,756.75 |
| October 2030 | 3,676.95 | 2,828.42 |
| November 2030 | 3,768.87 | 2,899.13 |
| December 2030 | 3,863.10 | 2,971.61 |
As we step into January 2030, Zydus Lifesciences is projected to reach a maximum price of 3,232.08 and a minimum price of 2,486.22. Moving through the year, February may see the maximum price rise to 3,314.95, with the minimum price at 2,549.96. By December, Zydus Lifesciences is expected to experience a maximum price of 3,863.10 and a minimum price of 2,971.61.
Financial Condition of Zydus Lifescience: Last 5 years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 |
| Expenses + | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 |
| Operating Profit | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 |
| OPM % | 20% | 24% | 22% | 22% | 28% |
| Other Income + | -264 | -231 | 2,581 | -422 | 293 |
| Interest | 342 | 159 | 127 | 130 | 81 |
| Depreciation | 696 | 670 | 713 | 723 | 764 |
| Profit before tax | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 |
| Tax % | 21% | 8% | 10% | 23% | 20% |
| Net Profit + | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 |
| EPS in Rs | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 |
| Dividend Payout % | 30% | 17% | 6% | 31% | 8% |
- Sales: Increased steadily from 14,253 in March 2020 to 19,547 in March 2024.
- Operating Profit: Notably rose from 2,798 in March 2020 to 5,384 in March 2024, with a peak operating profit margin (OPM) of 28% in March 2024.
- Profit Before Tax: Reached a peak of 5,084 in March 2022, indicating consistent profitability despite fluctuations.
- Net Profit: Demonstrated steady growth, peaking at 4,618 in March 2022.
- Earnings Per Share (EPS): Increased over the years, reflecting the growth in net profit.
- Dividend Payout Percentage: Varied, indicating the company’s strategy in balancing profits distribution to shareholders with reinvestment for growth.
- Overall Trend: Positive trajectory of growth and profitability evident in the financials from March 2020 to March 2024.
Sharekhan on Zydus Lifesciences Share Price Target
Sharekhan suggests buying Zydus Lifesciences with a target price of ₹1100.
FAQS
What is the current share price of Zydus Lifesciences?
As of 19th May 2024, the current share price of Zydus Lifesciences is ₹1,104.
What is the predicted share price target for Zydus Lifesciences by 2025?
Zydus Lifesciences’ share prices are expected to fluctuate between a projected high of ₹1,498.16 and an anticipated low of ₹981.08.
What is the predicted share price target for Zydus Lifesciences by 2030?
The forecasted maximum price prediction for Zydus Lifesciences in 2030 stands at ₹3,863.10, indicating a potential upward trajectory in the company’s share value.
What are some of the factors that may impact Zydus Lifesciences’ share price target in the coming years?
Some of the factors that may impact Zydus Lifesciences’ share price target include the company’s financial performance, changes in industry regulations, and global economic conditions.
Also Read
- Biocon Share Price Target 2024, 2025 to 2030
- Hindustan Aeronautics Ltd (HAL) Share Price Target 2024, 2025 to 2030
- Jindal Stainless Share Price Target 2024, 2025 to 2030
CONCLUSION
Zydus Lifesciences presents a compelling investment prospect within the pharmaceutical sector. The company’s sustained financial growth, driven by robust revenue and effective expense management, has established its prominence in the market. Furthermore, the recent authorization of a share buyback initiative demonstrates management’s confidence in and dedication to bolstering shareholder returns. Equipped with an innovative product lineup and strategic endeavors, Zydus Lifesciences is poised for ongoing prosperity amidst the dynamic healthcare environment, making it an appealing choice for investors seeking long-term opportunities.
Disclaimer: I do not hold Zydus Lifescience shares in my portfolio. And this is not a financial advice. We are not registered with SEBI.
Leave a Reply